Skip to main content

Invokana is Approved in Europe – An Exciting Year for SGLT-2s

Published: 1/21/14
By Adam Brown

On November 22, J&J/Janssen Cilags’ SGLT-2 inhibitor Invokana (canagliflozin) was approved in Europe. This makes Invokana the second SGLT-2 inhibitor approved in Europe, following BMS/AZ's Forxiga (dapagliflozin), which received approval in November 2012. Farxiga (the US name for Forxiga) was just approved in the US on January 8, 2014. Invokana and Farxiga are oral drugs that lower blood glucose by excreting excess glucose through urine. Invokana has been approved in the US since March 2013. This has been an exciting year for the brand new SGLT-2 inhibitor drug class, given the launch of Invokana in the US this past spring, the launch of Forxiga in Europe in December 2012, and the approval of Farxiga this January in the US. For more on Invokana, see our article on the US approval and our accompanying learning curve. –TW/AB

What do you think?

About the authors

Adam Brown joined diaTribe in 2010 as a Summer Associate, became Managing Editor in 2011, and served as Senior Editor through 2019. Adam brings almost two decades of personal experience... Read the full bio »